The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Objective To compare the therapeutic response to pregabalin in patients with moderate or severe painful diabetic peripheral neuropathy (pDPN). Research design and methods Data were pooled from 11 placebo-controlled trials to evaluate the efficacy of pregabalin flexible or fixed dose (150, 300 or 600 mg/day) in pDPN patients with mean baseline pain scores of ≥4 to <7 (moderate) or ≥7 to ≤10 (severe). Last observation carried forward imputation was used. Study number/ClinicalTrials.gov identifier 1008-014/-, 1008-029/-, 1008-040/-, 1008-131/-, 1008-149/-, 1008-000-155/-, A0081030/NCT00156078, A0081060/NCT00159679, A0081071/NCT00143156, A0081081/NCT00301223, A0081163/NCT00553475. Main outcome measures Pregabalin-mediated change in pain, pain-related sleep interference (PRSI) and patient global impression of change (PGIC) were compared versus placebo and between moderate and severe pain cohorts. Adverse events (AEs) were reported. Results At baseline, 1816 patients had moderate pain (pregabalin, n = 1189) and 1119 patients had severe pain (pregabalin, n = 720). Pregabalin significantly reduced pain scores at endpoint compared with placebo when patients of all pain levels were combined (all doses; p < 0.05). In the moderate and severe pain cohorts, pregabalin treatment (300, 600 mg/day or flexible) significantly reduced mean pain scores at endpoint compared with placebo (p < 0.01). Pain reduction was greatest in patients with severe baseline pain compared with moderate baseline pain (pregabalin 300, 600 mg/day or flexible; p < 0.0001). Pregabalin improved PRSI and PGIC in the moderate and severe cohorts compared with placebo. The greatest improvement in PRSI also occurred in the severe cohort. Treatment-emergent AEs, most commonly dizziness, somnolence and peripheral edema, occurred more frequently in patients treated with pregabalin compared with placebo. Conclusions Pregabalin was effective in pDPN patients with both moderate and severe baseline pain. Patients with severe pain exhibited greater improvements in pain and PRSI than patients with moderate pain. Pain severity may, in part, predict therapeutic response to pregabalin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At present, among pharmacological options, pregabalin588–598 and duloxetine594,595,599,600 are oral agents that have received regulatory approval for the treatment of neuropathic pain associated with DPN by the FDA and are effective for DPN pain reduction when using patient-reported outcomes.547”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [588]
Citations
Cites
Farrar, J. T., Young, J. P., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001) · Pain · doi:10.1016/s0304-3959(01)00349-9 · Cited by 5,808
The short-form McGill pain questionnaire
Melzack, R. (1987) · Pain · doi:10.1016/0304-3959(87)91074-8 · Cited by 4,368
Dworkin, R. H., Turk, D. C., Wyrwich, K. W., Beaton, D., Cleeland, C. S., Farrar, J. T., Haythornthwaite, J. A., Jensen, M. P., Kerns, R. D., Ader, D. N., et al. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.005 · Cited by 3,471
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
Neuropathic pain in the general population: A systematic review of epidemiological studies
van Hecke, O., Austin, S. K., Khan, R. A., Smith, B. H., & Torrance, N. (2014) · Pain · doi:10.1016/j.pain.2013.11.013 · Cited by 1,602
Dworkin, R. H., O'Connor, A. B., Audette, J., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., LeBel, A. A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,325
International association for the study of pain
Cousins, M. (1989) · Pain · doi:10.1016/0304-3959(89)90017-1 · Cited by 1,202
Smith, M. T., & Haythornthwaite, J. A. (2004) · Sleep Medicine Reviews · doi:10.1016/s1087-0792(03)00044-3 · Cited by 914
EFNS guidelines on pharmacological treatment of neuropathic pain
Attal, N., Cruccu, G., Haanpää, M., Hansson, P., Jensen, T. S., Nurmikko, T., Sampaio, C., Sindrup, S., & Wiffen, P. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01511.x · Cited by 880
The Prevalence, Severity, and Impact of Painful Diabetic Peripheral Neuropathy in Type 2 Diabetes
Davies, M., Brophy, S., Williams, R., & Taylor, A. (2006) · Diabetes Care · doi:10.2337/dc05-2228 · Cited by 746
Research works printed but not linked: 1
- Pal D, 2007, Indian J Med Res, 125, 721
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy
Jang, H. N., & Oh, T. J. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0018 · Cited by 106
Mallick‐Searle, T., & Adler, J. A. (2024) · Journal of Pain Research · doi:10.2147/jpr.s442595 · Cited by 57
Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review
Azmi, S., Elhadd, K. T., Nelson, A., Chapman, A., Bowling, F. L., Perumbalath, A., Lim, J. Z. M., Marshall, A. G., Malik, R. A., & Alam, U. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0550-x · Cited by 53
Metadata
- Authors
- Parsons, B., & Li, C.
- Affiliations
- Pfizer (United States) (US)
- Corresponding author
- Parsons, Bruce
- ORCID
- Parsons, Bruce
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2016-03-08
- Volume
- 32
- Issue
- 5
- Pages
- 929-937
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2280631568
- Cited by
- 20
- References
- 39
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 2 · 2019: 3 · 2018: 7 · 2017: 2 · 2016: 1
- FWCI
- 0.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- pregabalin, diabetic neuropathic pain, neuropathic pain, pain intensity, Patient Global Impression of Change, adverse events, dose comparison, flexible dosing, meta-analysis of trials, treatment efficacy, sleep disorders, quality of life, anxiety, cognitive impairment, dizziness, sleepiness
- MeSH terms
- Pregabalin, Adult, Aged, Analgesics, Diabetic Neuropathies, Double-Blind Method, Female, gamma-Aminobutyric Acid, Humans, Male, Middle Aged, Neuralgia, Pain Measurement, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy. https://app.cochat.ai/papers/10.1185/03007995.2016.1151776
- The paper
- Parsons, B., & Li, C. (2016). The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy. Current Medical Research and Opinion. https://doi.org/10.1185/03007995.2016.1151776
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.